The filing of a provisional patent for the MNPR-101 program by Monopar Therapeutics is a critical strategic move. It not only aims to protect the company's intellectual property but also potentially enhances the clinical profile of its leading program. This could lead to increased investor confidence in the company's pipeline and its ability to bring innovative cancer treatments to market. The direct mention of the patent filing and its significance to Monopar's strategy suggests a positive short-term impact on the company's stock price, as it demonstrates progress in its research and development efforts.